We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.


GlaxoSmithKline Extends GeneGo License and Adds New Products

Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "GlaxoSmithKline Extends GeneGo License and Adds New Products"

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

Read time:

GeneGo, Inc. announced that GlaxoSmithKline has extended their licensing agreement with GeneGo and have added additional capability. This will provide GlaxoSmithKline researchers with global access to MetaCore, MapEditor and MetaBase.

MetaCore is GeneGo’s flagship platform for functional analysis of biological OMICs data featuring a comprehensive collection of pathway maps and network models for cellular processes and common diseases.

MetaCore is used for target identification, validation, biomarker discovery and knowledge mining. GlaxoSmithKline will also use the platform as a repository of all types of experimental data as well as resulting analyses.

All of this information can be shared with individuals or groups. MetaBase is direct access to the manually curated database of pathways, networks, ontologies, medicinal chemistry and diseases covering human, mouse and rat. MapEditor is a powerful research tool for creating intereractive custom maps which amalgamate MetaBase knowledge content with proprietary information and data.

“We have a good working relationship with GlaxoSmithKline developing new products such as our pay as you go 1-2-3 Workflow,” said Julie Bryant, GeneGo’s VP of Business development. “We will continue to work closely developing new functionality, tools and content for GlaxoSmithKline.”